Within 14 days of registration, before each cycle, and at PD, patients underwent toxic effect assessments. Tumor assessments were performed after every 2 cycles.
Adverse Event Monitoring in Alisertib-Fulvestrant Trial
Within 14 days of registration, before each cycle, and at PD, patients underwent toxic effect assessments. Tumor assessments were performed after every 2 cycles.
Corresponding Organization :
Other organizations : Mayo Clinic, Mayo Clinic in Florida, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, University of Michigan–Ann Arbor, Duke University, Georgetown University, Albert Einstein College of Medicine, Montefiore Medical Center, University of Pennsylvania, Vanderbilt University Medical Center
Variable analysis
- Alisertib dose levels/modifications
- Adverse events (AEs)
- Tumor assessments
- Fulvestrant was not modified for AEs
- If treatment with alisertib was paused due to toxic effects, then so was fulvestrant
- Positive control: Not specified
- Negative control: Not specified
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!